February 15, 2013

Jounce to focus on #cancer #immunotherapy

Third Rock Ventures Launches Jounce Therapeutics with $47 Million Series A to Transform Cancer Treatment

Cancer start-up will get $47m

Third Rock bankrolls cancer immunotherapy upstart with $47M A round

Having lived the early-2000s as an information technology (mostly, but with some life sciences investments because of our relationship with the National Cancer Institute) corporate VC, did I learn anything?

Yes, among them, watch for signs.

No comments:

Post a Comment